KR20050034584A - Ｓｉｒｓ/패혈증의 치료 및 예방 방법 및 이를 위한조성물 - Google Patents

Ｓｉｒｓ/패혈증의 치료 및 예방 방법 및 이를 위한조성물 Download PDF

Info

Publication number
KR20050034584A
KR20050034584A KR1020047005056A KR20047005056A KR20050034584A KR 20050034584 A KR20050034584 A KR 20050034584A KR 1020047005056 A KR1020047005056 A KR 1020047005056A KR 20047005056 A KR20047005056 A KR 20047005056A KR 20050034584 A KR20050034584 A KR 20050034584A
Authority
KR
South Korea
Prior art keywords
vpr protein
nucleic acid
pharmaceutical composition
vpr
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020047005056A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 비. 웨이너
카루피아 무투마니
Original Assignee
더 트러스티스 오브 더 유니버시티 오브 펜실바니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 filed Critical 더 트러스티스 오브 더 유니버시티 오브 펜실바니아
Publication of KR20050034584A publication Critical patent/KR20050034584A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020047005056A 2001-10-05 2002-10-07 Ｓｉｒｓ/패혈증의 치료 및 예방 방법 및 이를 위한조성물 Ceased KR20050034584A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32727001P 2001-10-05 2001-10-05
US60/327,270 2001-10-05

Publications (1)

Publication Number Publication Date
KR20050034584A true KR20050034584A (ko) 2005-04-14

Family

ID=23275849

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047005056A Ceased KR20050034584A (ko) 2001-10-05 2002-10-07 Ｓｉｒｓ/패혈증의 치료 및 예방 방법 및 이를 위한조성물

Country Status (8)

Country Link
US (1) US20050042202A1 (enExample)
EP (1) EP1453548A4 (enExample)
JP (1) JP2005523879A (enExample)
KR (1) KR20050034584A (enExample)
CN (1) CN1564696A (enExample)
AU (1) AU2002362753B9 (enExample)
CA (1) CA2462876A1 (enExample)
WO (1) WO2003030827A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012177075A3 (ko) * 2011-06-23 2013-03-28 주식회사 아리메드 항생제 및 라이소포스파티딜콜린을 포함하는 면역 증강 또는 세균성 감염 질환 치료용 조성물

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102191695B1 (ko) 2013-04-05 2020-12-16 바이오마크 파마슈티칼스 리미티드 전이 억제제
EP3541407A1 (en) * 2016-11-18 2019-09-25 Universitat de Barcelona Combined cd6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes
EP4125863A1 (en) * 2020-04-03 2023-02-08 Medsenic Use of an arsenic compound for treating a short or long cytokine storm in various autoimmune/inflammatory diseases in humans or animals
US20210325380A1 (en) * 2020-04-20 2021-10-21 EnLiSense, LLC Disease diagnostics using a multi-configurable sensing array

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4241046A (en) * 1978-11-30 1980-12-23 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US5036006A (en) * 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4875834A (en) * 1987-02-19 1989-10-24 Sanden Corporation Wobble plate type compressor with variable displacement mechanism
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5676954A (en) * 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5210019A (en) * 1990-03-30 1993-05-11 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Pseudomonas screening assay
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
DE4227454C1 (de) * 1992-08-19 1994-02-03 Henning Berlin Gmbh Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5874225A (en) * 1993-02-19 1999-02-23 Trustees Of The University Of Pennsylvania Identification of compounds that modulate HIV-1 vpr protein activity
US5614503A (en) * 1993-11-12 1997-03-25 Aronex Pharmaceuticals, Inc. Amphipathic nucleic acid transporter
US5739118A (en) * 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5804370A (en) * 1994-06-08 1998-09-08 Critichem Medical Products Limited Early diagnosis of sepsis utilizing antigen-antibody interactions amplified by whole blood chemiluminescence
JP3892902B2 (ja) * 1994-09-16 2007-03-14 ザ スクリップス リサーチ インスティチュート グラム陽性細菌及びマイコバクテリアの作用を阻止するための抗体の使用
US5763190A (en) * 1994-09-21 1998-06-09 The Trustees Of The University Of Pennsylvania Methods for the identification of compounds capable of inducing the nuclear translocation of a receptor complex comprising the glucocoticoid receptor type II and viral protein R interacting protein
US5780237A (en) * 1994-10-12 1998-07-14 Cell Therapeutics, Inc. Sepsis, adult respiratory distress syndrome, and systemic inflammatory response syndrome diagnostic
US5707618A (en) * 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
US5756283A (en) * 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US6077665A (en) * 1996-05-07 2000-06-20 The Board Of Trustees Of The Leland Stanford Junior University Rapid assay for infection in neonates
SE519350C2 (sv) * 1997-01-28 2003-02-18 Anette Carlsson Antibakteriellt protein med specifik effekt mot gram-negativa bakterier, farmaceutiskt aktiva fragment därav med samma specifika effekt, samt farmaceutisk komposition innehållande proteinet eller fragment därav
US6251598B1 (en) * 1998-10-30 2001-06-26 Interleukin Genetics, Inc. Methods for diagnosing sepsis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012177075A3 (ko) * 2011-06-23 2013-03-28 주식회사 아리메드 항생제 및 라이소포스파티딜콜린을 포함하는 면역 증강 또는 세균성 감염 질환 치료용 조성물

Also Published As

Publication number Publication date
CA2462876A1 (en) 2003-04-17
AU2002362753B9 (en) 2008-05-15
CN1564696A (zh) 2005-01-12
US20050042202A1 (en) 2005-02-24
WO2003030827A2 (en) 2003-04-17
WO2003030827A3 (en) 2003-07-17
AU2002362753B2 (en) 2007-11-15
EP1453548A4 (en) 2005-10-26
JP2005523879A (ja) 2005-08-11
EP1453548A2 (en) 2004-09-08

Similar Documents

Publication Publication Date Title
AU672606B2 (en) Methods for treating interleukin-1 and tumor necrosis factor mediated diseases
Tracey et al. Cachectin/tumor necrosis factor and other cytokines in infectious disease
JP2002543144A (ja) ＰＥＧ化インターフェロンαＣＣＲ５アンタゴニスト併用ＨＩＶ療法
Balsley et al. A cell-impermeable cyclosporine A derivative reduces pathology in a mouse model of allergic lung inflammation
RU2313364C2 (ru) Способы индукции длительного иммунного ответа
EP1608397A1 (en) S100 protein as neutrophil activator for alleviating neutropenia in cancer treatment
Apte et al. Opposing Effects of IL-1α and IL-1β on Malignancy Patterns: Tumor cell-associated IL-Iα potentiates anti-tumor immune responses and tumor regression, whereas IL-1β potentiates invasiveness
KR100837898B1 (ko) 다발성 경화증의 치료에서 사용되는 케모킨 변이체
WO2003037376A1 (fr) Prophylactiques et/ou remedes pour le traitement de l'arteriosclerose apres transplantation dans le cas de rejet de greffe
KR20050034584A (ko) Ｓｉｒｓ/패혈증의 치료 및 예방 방법 및 이를 위한조성물
WO2001034177A2 (en) Method of treating a viral infection using antagonists of macrophage colony stimulating factor
EP3484500A1 (en) Uses of il-12 as a replacement immunotherapeutic
AU2002362753A1 (en) Compositions for and methods of treating and preventing sirs/sepsis
US6497870B1 (en) Therapeutic uses of il-1 receptor antagonist
CN1469756A (zh) 治疗肝病的药物
JP2007530452A (ja) インターロイキン−τを用いる処置を最適化する方法
KR102030572B1 (ko) 방사선 완화제 및 방사선 방호제로서의 ｂｐｉ 및 이의 동질체
AU2005326226B2 (en) Immunopotentiating agent
CN117018202A (zh) 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用
JPH09510737A (ja) 化学療法剤を増強するためのｉｌ−４の使用
WO2024011946A1 (en) Polypeptide dimers for the treatment of systemic sclerosis
US6583110B1 (en) Use of agents which bind G proteins for treating septic shock
JP3258348B2 (ja) Ｈｉｖ感染阻害剤
JPH04270225A (ja) 悪液質の治療剤
JP2003063995A (ja) 免疫学的疾患の治療のための配合製剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20040406

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20071008

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20081118

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20090320

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20081118

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20090622

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20090320

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20101029

Appeal identifier: 2009101005626

Request date: 20090622

AMND Amendment
PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20090722

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20090622

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20090318

Patent event code: PB09011R02I

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20090806

Patent event code: PE09021S02D

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial

Comment text: Report of Result of Re-examination before a Trial

Patent event code: PB06011S01D

Patent event date: 20100303

J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20090622

Effective date: 20101029

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20101029

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20090622

Decision date: 20101029

Appeal identifier: 2009101005626